Padma P. Nanaware

455 citations
18 papers · 243 indexed · h-index 9

Padma P. Nanaware

17 papers receiving 242 citations

Peers

Padma P. Nanaware
Comparison fields: 5 of 58
  • Immunology 103
  • Reproductive Medicine 29
  • Infectious Diseases 33
  • Genetics 43
  • Immunology and Allergy 9
Replace Joris van Montfrans with:
Joris van Montfrans Netherlands
Manuela Meyer Germany
Ryohei Nishino Japan
Anja Honegger Germany
Adam R. Lefferts United States
Wenjing Tang China
M. Glaucia Teixeira United States
J. Omar Muñoz-Bello Mexico
Audrey Defusco United States
David Livingstone Alves Figueiredo Brazil
Padma P. Nanaware relative to Joris van Montfrans Netherlands Joris van Montfrans's profile →
Citations per field
00.5×3.2×
Joris van Montfrans · 1×
Citations per year

Countries citing papers authored by Padma P. Nanaware

Since Specialization
Citations

This map shows the geographic impact of Padma P. Nanaware's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Padma P. Nanaware with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Padma P. Nanaware more than expected).

Fields of papers citing papers by Padma P. Nanaware

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Padma P. Nanaware. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Padma P. Nanaware. The network helps show where Padma P. Nanaware may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Padma P. Nanaware, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Padma P. Nanaware Line = papers co-authored together Padma P. Nanaware links everyone, so they are left out of the graph.

All Works

18 of 18 papers shown
#Work
1 20250
2 20241
3 20236
4 20231
5 202310
6 202218
7 20223
8 20223
9 202110
10 202136
11 20212
12 20216
13 202029
14 20194
15 201830
16 201312
17 201331
18 201041

About Padma P. Nanaware

Padma P. Nanaware is a scholar working on Immunology, Cell Biology and Molecular Biology, having authored 18 papers that have together received 243 indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (7 papers), vaccines and immunoinformatics approaches (6 papers), T-cell and B-cell Immunology (4 papers), Immune Cell Function and Interaction (4 papers), SARS-CoV-2 and COVID-19 Research (3 papers), Ubiquitin and proteasome pathways (3 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and Diabetes and associated disorders (2 papers). The work is most often cited by research in Immunology (103 citations), Reproductive Medicine (29 citations) and Infectious Diseases (33 citations). Padma P. Nanaware has collaborated with scholars based in United States, India and Israel. Frequent co-authors include Lawrence J. Stern, Prasanna Venkatraman, Mollie Jurewicz, Arun Kumar Somavarapu, Scott A. Shaffer, Nafisa Balasinor, Zuping He, Ryan S. D’Souza, John Leszyk and Susan Idicula‐Thomas. Their work appears in journals such as Immunity, The Journal of Immunology and FEBS Letters.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026